Intermittent Negative Pressure; Impact on Peripheral Artery Disease &

Status Terminated

Clinical Trial Summary

The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market. The study will be carried out in a patient population with peripheral artery disease (claudicatio intermittens) to confirm its usefulness and in particular gather information for further improvements of the device related to this patient population. The data collected from the use of the CE-marked FlowOX™ device are change of walking distance, quality of life, and the patient's compliance.

Clinical Trial Description

A multi-center, randomized, sham (placebo)-controlled, double-blind trial to assess the efficacy and safety of FlowOx. This is done by comparing the increase in pain free walking distance compared to sham (placebo) device in patients with peripheral arterial disease (PAD) and intermittent claudication.

This study is conducted to assess the efficacy and safety of FlowOx™ compared to a sham FlowOx™ (placebo) device treatment. FlowOx™ can provide intermittent negative pressure (up to - 40 mmHg INP [intermittent negative pressure]) which is known to improve blood flow. The same device will also work as a sham (placebo) device by less negative pressure exerted by the device (in the range of -10 mmHg).

Daily home use of FlowOx™ for 2 hours (divided into minimum two sessions of 1 hour) per day in PAD-patients with intermittent claudication (stage II acc.to EMA, equivalent to Fontaine stage IIb in Germany) relative to sham (placebo) will be provided over a period of 12 weeks.

This efficacy study is evaluating the clinical effects of INP on patient with intermittent claudication with special focus on changes in pain free walking distance and quality of life. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04100681
Study type	Interventional
Source	Otivio AS
Contact
Status	Terminated
Phase	N/A
Start date	August 19, 2019
Completion date	May 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03987061` - MOTIV Bioresorbable Scaffold in BTK Artery Disease	N/A
Recruiting	`NCT03668353` - Recombinant SeV-hFGF2/dF Injection for PAOD	Phase 1
Recruiting	`NCT04110964` - Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT	Phase 1
Not yet recruiting	`NCT03994666` - Cell Therapy in Critical Limb Ischemia	Phase 2
Recruiting	`NCT02389023` - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery	N/A
Not yet recruiting	`NCT02498080` - Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia	N/A
Completed	`NCT02539940` - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Recruiting	`NCT02239419` - Evaluation of Carbothera in the Treatment of Foot Ulcers	N/A
Recruiting	`NCT01938872` - Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia	N/A
Active, not recruiting	`NCT01211925` - Distal Venous Arterialisation of Ischemic Limb	Phase 2/Phase 3
Completed	`NCT02454231` - Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)	Phase 2/Phase 3
Completed	`NCT01758874` - Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia	Phase 2
Completed	`NCT02475200` - Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
Recruiting	`NCT04583436` - Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia	N/A
Completed	`NCT04071782` - Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore	N/A
Completed	`NCT03669458` - Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.	N/A
Not yet recruiting	`NCT06007469` - Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
Recruiting	`NCT04110327` - An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Completed	`NCT02260622` - Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia	Phase 2
Recruiting	`NCT02054416` - External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication — FlowOx

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms